Publications

Kumar, R. (2019) “Get Real and Get It Right With Type 2 Diabetes: It Is Time For A Paradigm Shift” published on LinkedIn, March 27, 2019.

Kumar, R. (2016) Anti-inflammatory Centric Drug Combination Lowers Non-fasting and Fasting Blood Glucose Levels in C57BL/6 DIO Mice with Insulin Resistance. Diabetes 65 (Suppl.1): A294. 2016-A-3237-Diabetes. 76th Scientific Sessions of the American Diabetes Association (June 10-14, 2016), New Orleans, LA.                  

Schwartz, S.S. et al. (2016) The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the ß-Cell-Centric Classification Schema. Diabetes Care 39:179–186.

Skyler, J.S. et al. (2017) Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes 66:241-255. DOI: 10.2337/db16-0806.

Seferovic, J.P. et al (2017) Effect of sacubitril/valsartan versus enalapril on glycemic control in patients with heart failure and diabetes: A post-hoc analysis from the PARADIGM-HF trial. THE LANCET Diabetes & Endocrinology. Published Online March 18, 2017.

Lu, C.H. et al. (2016) Additional Effect of Metformin and Celecoxib Against Lipid dysregulation and Adipose Tissue Inflammation in High-fat Fed Rats with Insulin Resistance and Fatty Liver. Eur. J. Pharmacol. 789: 60-67.

Nissen, S.E. et al. (2016) Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New Engl. J. Med. 375(26): 2519-2529. DOI: 10.1056/NEJMoa1611593

Vinik, A.I. (2004) Inflammation: The Root of all Evil in Diabetes and Dysmetabolic Syndrome. (Create an account with login information at medscape.com to access the article)

Kumar, R. (2021) TriGlytza™: Clinical PoC for Counter-Regulation of RAAS-AngII-Cox2-PGE2 Axis for Treatment and Mitigation of ARDS and MODS Associated with COVID-19. Published on Linkedin, October 5, 2021.